A Hyeon Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
A Hyeon Lee has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dae Won Jun
Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea
2 shared publications - Eileen Laurel Yoon
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
2 shared publications - Seung Min Lee
Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea
2 shared publications - Gye Ryeol Park
Department of Translational Medicine, Graduate School of Biomedical Science and Engineering Hanyang University Seoul South Korea
1 shared publication - Gye Ryeol Park
Department of Translational Medicine, Graduate School of Biomedical Science & Engineering, Hanyang University, Seoul 04763, Republic of Korea
1 shared publication - Hye Hyun Yoo
Pharmacomicrobiomics Research Center, College of Pharmacy, Hanyang University, Ansan 15588, Republic of Korea
1 shared publication
Latest Publications
- Open Access
VSL#3 Co-Administration Is Associated with Altered Early-Phase Obeticholic Acid Exposure in MASLD Mice
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and its global incidence continues to increase. MASLD can progress from simple steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, effective preventive and therapeutic options remain limited. In this study, obeticholic acid (OCA) and the probiotic mixture VSL#3 were co-administered to a mouse model of MASLD to modulate gut microbiota and bile acid metabolism. Methods: Male C57BL/6 mice were fed a WD to induce MASLD and treated with OCA, VSL#3, or both. Gut microbiota was analyzed by 16S rRNA sequencing, bile acid (BA) composition was assessed by LC–MS/MS, hepatic and intestinal gene expression was determined by quantitative real-time PCR (qPCR) and immunohistochemistry, and unconjugated OCA pharmacokinetics (PK) were evaluated. Results: VSL#3-containing groups showed differences in selected taxa with reported bile salt hydrolase (BSH) potential and in BA composition, including a numerical shift toward higher levels of deconjugated BAs. Co-administration of OCA and VSL#3 was accompanied by lower hepatic steatosis, numerically favorable serum markers of liver injury, and lower cholesterol and total bilirubin levels. In addition, mice receiving VSL#3 showed numerically higher early plasma concentrations of unconjugated OCA. Lower intestinal ATP-binding cassette subfamily C member 2 (Abcc2) expression was also observed as a separate exploratory finding. Conclusions: The co-administration of VSL#3 with OCA was accompanied by exploratory differences in selected biological parameters and early-phase unconjugated OCA exposure. Lower intestinal Abcc2/Mrp2 expression was observed as a separate exploratory finding, and no functional relationship between intestinal transporter expression and OCA pharmacokinetics was established.
Open AccessVSL#3 Co-Administration Is Associated with Altered Early-Phase Obeticholic Acid Exposure in MASLD Mice
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and its global incidence continues to increase. MASLD can progress from simple steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, effective preventive and therapeutic options remain limited. In this study, obeticholic acid (OCA) and the probiotic mixture VSL#3 were co-administered to a mouse model of MASLD to modulate gut microbiota and bile acid metabolism. Methods: Male C57BL/6 mice were fed a WD to induce MASLD and treated with OCA, VSL#3, or both. Gut microbiota was analyzed by 16S rRNA sequencing, bile acid (BA) composition was assessed by LC–MS/MS, hepatic and intestinal gene expression was determined by quantitative real-time PCR (qPCR) and immunohistochemistry, and unconjugated OCA pharmacokinetics (PK) were evaluated. Results: VSL#3-containing groups showed differences in selected taxa with reported bile salt hydrolase (BSH) potential and in BA composition, including a numerical shift toward higher levels of deconjugated BAs. Co-administration of OCA and VSL#3 was accompanied by lower hepatic steatosis, numerically favorable serum markers of liver injury, and lower cholesterol and total bilirubin levels. In addition, mice receiving VSL#3 showed numerically higher early plasma concentrations of unconjugated OCA. Lower intestinal ATP-binding cassette subfamily C member 2 (Abcc2) expression was also observed as a separate exploratory finding. Conclusions: The co-administration of VSL#3 with OCA was accompanied by exploratory differences in selected biological parameters and early-phase unconjugated OCA exposure. Lower intestinal Abcc2/Mrp2 expression was observed as a separate exploratory finding, and no functional relationship between intestinal transporter expression and OCA pharmacokinetics was established.
- 9 October 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (12) , 2206-2214
Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis
Background and Aim: Necroptosis is an emerging cell death pathway that allows cells to undergo “cellular suicide” in a caspase‐independent manner. We investigated the fate of hepatic stellate cells (HSCs) under necroptotic stimuli.Methods and Results: The RNA level of mixed lineage kinase domain‐like protein (MLKL) is higher in patients with non‐alcoholic fatty liver disease than in healthy controls. Hepatic fibrosis was significantly lower in MLKL‐KO bile duct ligation (KO‐BDL) mice than in wild‐type‐BDL mice. Necroptotic stimuli caused the death of HT‐29 and U937 cells. However, necroptotic stimuli activate HSCs instead of inducing cell death. MLKL inhibitors attenuated fibrogenic changes in HSCs during necroptosis. Unlike HT‐29 and U937 cells, MLKL phosphorylation and oligomerization were not observed during necroptosis in HSCs. RNA sequencing showed that NF‐κB signaling‐related genes were upregulated in HSCs following necroptotic stimulation. Necroptotic stimuli in HSCs increased the nuclear expression of NF‐κB, which decreased after MLKL inhibitor treatment. Induction of necroptosis in HSCs led to autophagosome activation and formation, which were attenuated by MLKL inhibitor treatment.Conclusion: HSCs avoid necroptosis due to the absence of MLKL phosphorylation and oligomerization and are activated through autophagosome and NF‐κB pathways.
- 9 October 2023
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 38 (12) , 2206-2214
Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis
Background and Aim: Necroptosis is an emerging cell death pathway that allows cells to undergo “cellular suicide” in a caspase‐independent manner. We investigated the fate of hepatic stellate cells (HSCs) under necroptotic stimuli.Methods and Results: The RNA level of mixed lineage kinase domain‐like protein (MLKL) is higher in patients with non‐alcoholic fatty liver disease than in healthy controls. Hepatic fibrosis was significantly lower in MLKL‐KO bile duct ligation (KO‐BDL) mice than in wild‐type‐BDL mice. Necroptotic stimuli caused the death of HT‐29 and U937 cells. However, necroptotic stimuli activate HSCs instead of inducing cell death. MLKL inhibitors attenuated fibrogenic changes in HSCs during necroptosis. Unlike HT‐29 and U937 cells, MLKL phosphorylation and oligomerization were not observed during necroptosis in HSCs. RNA sequencing showed that NF‐κB signaling‐related genes were upregulated in HSCs following necroptotic stimulation. Necroptotic stimuli in HSCs increased the nuclear expression of NF‐κB, which decreased after MLKL inhibitor treatment. Induction of necroptosis in HSCs led to autophagosome activation and formation, which were attenuated by MLKL inhibitor treatment.Conclusion: HSCs avoid necroptosis due to the absence of MLKL phosphorylation and oligomerization and are activated through autophagosome and NF‐κB pathways.